What is Xention?
Xention operates at the intersection of advanced pharmacology and cardiovascular medicine, focusing on the discovery and development of small-molecule drugs that target specific ion channels. By prioritizing the treatment of atrial fibrillation, the company has carved out a niche in the high-stakes biotech sector. Its innovative approach to modulating Kv1.5 and Kir3.1/3.4 channels positions Xention as a critical player in the development of next-generation therapeutics. The company's operational model relies on a blend of internal R&D excellence and high-value strategic partnerships, such as its collaboration with Servier, which validates its scientific methodology and commercial viability in the global pharmaceutical landscape.
How much funding has Xention raised?
Xention has raised a total of $44.9M across 4 funding rounds:
Series A
$5.7M
Series C
$6.5M
Series B
$20M
Series D
$12.7M
Series A (2003): $5.7M with participation from Albany Ventures, MVM Life Science Partners, SPARK Ventures, and BTG
Series C (2003): $6.5M led by MVM Life Science Partners and BTG International
Series B (2005): $20M supported by MVM, Quester, Enterprise VCT plc, Isis Equity Partners, BTG International, ABN AMRO Capital of Amsterdam, Cr�dit Agricole Private Equity, and Albany Ventures
Series D (2010): $12.7M featuring Seroba-Kernel Life Sciences Ltd
Key Investors in Xention
Seroba-Kernel Life Sciences Ltd
A European life sciences venture capital firm focused on investing in biotech and medtech innovations to support entrepreneurs in realizing their scientific ambitions.
MVM Life Science Partners
A specialized investment firm dedicated to the life sciences sector, providing capital and strategic guidance to companies developing transformative healthcare solutions.
BTG International
A global healthcare company focused on developing and commercializing products for specialized hospital and emergency medicine markets.
What's next for Xention?
Looking ahead, Xention is poised to leverage its historical funding trajectory to transition from early-stage discovery into more advanced clinical milestones. The strategic allocation of capital will likely be directed toward accelerating the Kv1.5 program and expanding its therapeutic reach. As the company continues to refine its ion channel-modulating platform, the focus will shift toward regulatory engagement and the potential for further commercial partnerships. By maintaining a disciplined approach to drug design and clinical validation, Xention is well-positioned to capitalize on the growing demand for targeted cardiovascular treatments, potentially setting the stage for future liquidity events or expanded licensing agreements.
See full Xention company page
